Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Neoplasms

Neoplasms

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Neoplasms

159 trials tracked for Neoplasms: 12 in phase 3 or 4 and 5 with published results. The most-cited published study has 722 citations.

159Trials tracked
12Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 4 Phase 3 8 Phase 2 38 Phase 1 90 Other / NA 19
  1. Phase 3 A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants Completed · 722 cited
  2. Phase 3 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Completed · 135 cited
  3. Phase 3 CORAL XT - Open-label Extension Trial of the CORAL Trial Completed · 34 cited
  4. Phase 3 A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer Completed · 26 cited
  5. Phase 4 An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study Completed · 19 cited
  6. Phase 4 An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol Completed
Show 44 more trials
  1. Phase 4 Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Completed
  2. Phase 4 A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia Completed
  3. Phase 3 Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction Completed
  4. Phase 3 Sorafenib Long Term Extension Program Completed
  5. Phase 3 A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants Completed
  6. Phase 3 XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer Completed
  7. Phase 2 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Completed
  8. Phase 2 A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation Completed
  9. Phase 2 A Trial for Patients With Advanced/Recurrent Endometrial Cancer Completed
  10. Phase 2 Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer Completed
  11. Phase 2 Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma Completed
  12. Phase 2 A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued. Completed
  13. Phase 2 Yoga Cancer Rehabilitation Study: A Randomized Trial of Adaptive Yoga for Older Cancer Survivors Completed
  14. Phase 2 Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1 Completed
  15. Phase 2 Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer Completed
  16. Phase 2 A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer Completed
  17. Phase 2 Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours Completed
  18. Phase 2 Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Completed
  19. Phase 2 A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders Completed
  20. Phase 2 A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer Completed
  21. Phase 2 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Completed
  22. Phase 2 A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer Completed
  23. Phase 2 Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer Completed
  24. Phase 2 Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3 Completed
  25. Phase 2 A Study of AK-01 (LY3295668) in Solid Tumors Completed
  26. Phase 2 Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer Completed
  27. Phase 2 Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator. Completed
  28. Phase 2 GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Completed
  29. Phase 2 Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer Completed
  30. Phase 2 A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children Completed
  31. Phase 2 Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors Completed
  32. Phase 2 Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma Completed
  33. Phase 2 Open Label Extension In Cancer Patients Completed
  34. Phase 2 An Open Label Study of Oral Enzastaurin in Participants With Cancer Completed
  35. Phase 2 A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies Completed
  36. Phase 2 Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) Completed
  37. Phase 2 A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers Completed
  38. Phase 2 Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma Completed
  39. Phase 2 A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) Completed
  40. Phase 2 My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Completed
  41. Phase 2 Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II) Completed
  42. Phase 2 A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract. Completed
  43. Phase 2 Methylnaltrexone for Opioid-induced Constipation in Cancer Patients Completed
  44. Phase 2 High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy Completed

Showing the 50 most-cited and recently-updated of 159 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Neoplasms: what the trials found

Several agents have been evaluated for the management of neoplasms, with varying outcomes in efficacy and safety. Bevacizumab showed adverse event rates ranging from 71.4% to 100.0% 5. Everolimus demonstrated clinical benefit in approximately 7% to 9% of patients across different cohorts, with associated adverse events reported at 1% to 9% 6. Vemurafenib was associated with adverse or serious adverse events in 19.9% to 93.2% of participants depending on the cohort 7.

In specific clinical contexts, Sorafenib showed a range of severe treatment-related adverse events (CTCAE Grade 3 or higher) across different arms 13. Nab-paclitaxel demonstrated a statistically significant improvement in Overall Survival (OS) with p=0.0128 10, while the reported number of high-grade laboratory abnormalities was low across groups 10. Cabazitaxel showed statistically significant improvements in Overall Survival (p<0.0001), Progression Free Survival (p<0.0001), and Overall Tumor Response (p=0.0005) 16.

Other treatments included Herceptin, where zero participants experienced a drop in Left Ventricular Ejection Fraction below 45% 12, and Rivaroxaban, which showed no statistically significant difference in the time to first occurrence of major bleeding events (p=0.265) or primary efficacy endpoints (p=0.101) 9. For pain management in oncology settings, Tapentadol ER resulted in 84% to 98% of patients achieving pain control 15, while Botulinum Toxin Type A did not show a statistically significant difference in average pain scores compared to the control (p=0.43) 14.

Recent results — preliminary, needs further review

  • BI 754091 showed no dose-limiting toxicities in Phase Ia, but reported adverse events in 96.3% to 100% of participants and serious adverse events in 25.9% to 48.4% of patients during Phase Ib 2.
  • Ezabenlimab demonstrated disease control rates ranging from 38.9% to 86.7% across different cohorts 3.
  • CC-90011 was associated with varying numbers of high-grade hematology and chemistry toxicities, as well as post-baseline ECOG status shifts 21.
  • Trastuzumab showed disease control rates ranging from 16.2% to 66.7% across various tumor-pathway cohorts 22.
  • Dostarlimab was evaluated for hematology and clinical chemistry results, with varying counts of high-grade increases across arms 17.

For the clinician treating this condition

  • Cabazitaxel demonstrated statistically significant improvements in OS, PFS, and overall tumor response compared to the control 16.
  • Nab-paclitaxel showed a statistically significant improvement in Overall Survival (p=0.0128) 10.
  • Treatment outcomes for newer agents like Ezabenlimab and Trastuzumab show varying rates of disease control across different patient cohorts [3, 22].

AI synthesis of 15 cited trials, updated Jul 10, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Photoacoustic imaging enables label-free real-time tumor microenvironment visualization in oncology
Allergy & Immunology Sys. Review
Photoacoustic imaging enables label-free real-time tumor microenvironment visualization in oncology New imaging technology helps doctors see tumor details in real time
This systematic review examines photoacoustic imaging (PAI) for oncology applications, highlighting its ability to provide label-free, real-…
A new type of imaging uses light to map oxygen levels and blood flow in tumors, helping surgeons see more during cancer treatment.
Frontiers Aug 21, 2026
CXCL16/CXCR6 axis exerts bidirectional regulatory influence on neoplasms and inflammatory disorders like asthma
Oncology Sys. Review
CXCL16/CXCR6 axis exerts bidirectional regulatory influence on neoplasms and inflammatory disorders like asthma New Biological Pathways May Help Doctors Treat Cancer and Asthma Better
This narrative review examines the CXCL16/CXCR6 axis as a multifaceted regulator in various pathological processes, including neoplasms and …
Scientists are looking at how a specific protein pathway can influence both cancer growth and lung inflammation.
Frontiers Jul 23, 2026
Tumor Treating Fields and pulsed electric fields modulate cell death and immune microenvironment in neoplasms
Oncology Sys. Review
Tumor Treating Fields and pulsed electric fields modulate cell death and immune microenvironment in neoplasms Electric fields may help fight tumors and overcome treatment resistance
This systematic review examines the mechanisms of electrical stress transduction into biochemical signals. The authors synthesize evidence t…
New research explores how electric fields can trigger cell death in tumors and help the body's immune system fight cancer more effectively.
Frontiers Jul 9, 2026